Extending the chimeric receptor-based T-cell targeting strategy to solid tumors.

The adoptive transfer of T cells expressing chimeric antigen receptors (Cars) has emerged as a promising immunotherapeutic strategy against cancer. administering Car-expressing T cells in combination with agents that promote the expression of Car targets or optimize T-cell function within the tumor microenvironment may further improve the therapeutic potential of this approach. [ABSTRACT FROM AUTHOR]